These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 17391488)

  • 1. Management of acute graft-versus-host disease.
    Bacigalupo A
    Br J Haematol; 2007 Apr; 137(2):87-98. PubMed ID: 17391488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunopathogenesis of acute graft-versus-host disease: implications for novel preventive and therapeutic strategies.
    Zeiser R; Marks R; Bertz H; Finke J
    Ann Hematol; 2004 Sep; 83(9):551-65. PubMed ID: 15449032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylaxis and treatment of acute graft-versus-host disease.
    Chao NJ; Chen BJ
    Semin Hematol; 2006 Jan; 43(1):32-41. PubMed ID: 16412787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone marrow transplantation: new approaches to immunosuppression and management of acute graft-versus-host disease.
    Auletta JJ; Cooke KR
    Curr Opin Pediatr; 2009 Feb; 21(1):30-8. PubMed ID: 19242239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Graft-versus-host disease: review and nursing implications.
    Mattson MR
    Clin J Oncol Nurs; 2007 Jun; 11(3):325-8. PubMed ID: 17623617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
    Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
    Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Graft vs host disease].
    Moalic V; Ferec C
    Pathol Biol (Paris); 2006 May; 54(5):304-8. PubMed ID: 16530350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
    Strober S
    Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation.
    Tian Y; Deng YB; Huang YJ; Wang Y
    Immunol Invest; 2008; 37(1):29-42. PubMed ID: 18214798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colonic graft-versus-host disease.
    Ross WA; Couriel D
    Curr Opin Gastroenterol; 2005 Jan; 21(1):64-9. PubMed ID: 15687887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Administration of short-term immunosuppressive agents after DLI reduces the incidence of DLI-associated acute GVHD without influencing the GVL effect.
    Huang XJ; Wang Y; Liu DH; Xu LP; Liu KY; Chen H; Chen YH; Han W; Shi HX
    Bone Marrow Transplant; 2009 Sep; 44(5):309-16. PubMed ID: 19234512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management.
    Couriel D; Caldera H; Champlin R; Komanduri K
    Cancer; 2004 Nov; 101(9):1936-46. PubMed ID: 15372473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced intensity conditioning for allogeneic hematopoietic stem-cell transplant determines the kinetics of acute graft-versus-host disease.
    Turner BE; Kambouris ME; Sinfield L; Lange J; Burns AM; Lourie R; Atkinson K; Hart DN; Munster DJ; Rice AM
    Transplantation; 2008 Oct; 86(7):968-76. PubMed ID: 18852664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
    J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma.
    Bloor AJ; Thomson K; Chowdhry N; Verfuerth S; Ings SJ; Chakraverty R; Linch DC; Goldstone AH; Peggs KS; Mackinnon S
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):50-8. PubMed ID: 18158961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of acute graft versus host disease (GvHD).
    Bacigalupo A; Palandri F
    Hematol J; 2004; 5(3):189-96. PubMed ID: 15167903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic graft-versus-host disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. A report from the Japan Marrow Donor Program.
    Ozawa S; Nakaseko C; Nishimura M; Maruta A; Cho R; Ohwada C; Sakamaki H; Sao H; Mori S; Okamoto S; Miyamura K; Kato S; Kawase T; Morishima Y; Kodera Y;
    Br J Haematol; 2007 Apr; 137(2):142-51. PubMed ID: 17391494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An overview of chronic oral graft-vs-host disease following pediatric hematopoietic stem cell transplantation.
    da Fonseca MA; Hong C
    Pediatr Dent; 2008; 30(2):98-104. PubMed ID: 18481573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy by allogeneic stem cell transplantation.
    Ringdén O
    Adv Cancer Res; 2007; 97():25-60. PubMed ID: 17419940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.